Back to search
HRD-negative Epithelial Ovarian Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which HRD-negative Epithelial Ovarian Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which HRD-negative Epithelial Ovarian Cancer trials you may qualify forThis is a prospective, multicenter, phase II study designed to evaluate the efficacy and safety of disitamab vedotin combined with platinum plus bevacizumab as…
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous…
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated tha…
This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated exploratory study designed to evaluate the safety, tolerability and p…
NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors. The Phase 1 and 1b portions i…